- Home
- WRBY vs VRDN Comparison
WRBY vs VRDN Comparison
Compare WRBY & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WRBY
- VRDN
- Stock Information
- Founded
- WRBY 2010
- VRDN 2006
- Country
- WRBY United States
- VRDN United States
- Employees
- WRBY N/A
- VRDN N/A
- Industry
- WRBY Ophthalmic Goods
- VRDN Medical Specialities
- Sector
- WRBY Health Care
- VRDN Health Care
- Exchange
- WRBY Nasdaq
- VRDN Nasdaq
- Market Cap
- WRBY 1.7B
- VRDN 1.6B
- IPO Year
- WRBY 2021
- VRDN N/A
- Fundamental
- Price
- WRBY $15.53
- VRDN $13.50
- Analyst Decision
- WRBY Buy
- VRDN Buy
- Analyst Count
- WRBY 14
- VRDN 12
- Target Price
- WRBY $23.79
- VRDN $36.44
- AVG Volume (30 Days)
- WRBY 2.7M
- VRDN 1.1M
- Earning Date
- WRBY 05-08-2025
- VRDN 05-07-2025
- Dividend Yield
- WRBY N/A
- VRDN N/A
- EPS Growth
- WRBY N/A
- VRDN N/A
- EPS
- WRBY N/A
- VRDN N/A
- Revenue
- WRBY $771,315,000.00
- VRDN $302,000.00
- Revenue This Year
- WRBY $17.29
- VRDN N/A
- Revenue Next Year
- WRBY $13.74
- VRDN $20,553.29
- P/E Ratio
- WRBY N/A
- VRDN N/A
- Revenue Growth
- WRBY 15.16
- VRDN N/A
- 52 Week Low
- WRBY $11.66
- VRDN $9.90
- 52 Week High
- WRBY $28.68
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- WRBY 42.22
- VRDN 49.53
- Support Level
- WRBY $13.63
- VRDN $9.90
- Resistance Level
- WRBY $16.17
- VRDN $14.61
- Average True Range (ATR)
- WRBY 1.23
- VRDN 1.07
- MACD
- WRBY 0.28
- VRDN 0.28
- Stochastic Oscillator
- WRBY 56.23
- VRDN 76.43
About WRBY Warby Parker Inc.
Warby Parker Inc is a mission-driven, lifestyle brand that operates at the intersection of design, technology, healthcare, and social enterprise. The company predominantly derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.